NA
LTRN icon

NewEdge Advisors’s Lantern Pharma LTRN Stock Holding History

NewEdge Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.5K Sell
27,399
-10,670
-28% -$29.8K ﹤0.01% 3012
2025
Q4 		$115K Sell
38,069
-9,210
-19% -$34.3K ﹤0.01% 2727
2025
Q3 		$206K Sell
47,279
-9,228
-16% -$38.5K ﹤0.01% 2400
2025
Q2 		$179K Sell
56,507
-3,417
-6% -$11.5K ﹤0.01% 2253
2025
Q1 		$212K Sell
59,924
-8,435
-12% -$35K ﹤0.01% 2067
2024
Q4 		$218K Sell
68,359
-68,979
-50% -$236K ﹤0.01% 2050
2024
Q3 		$504K Sell
137,338
-19,786
-13% -$81.5K ﹤0.01% 1480
2024
Q2 		$734K Sell
157,124
-3,408
-2% -$20.5K 0.01% 1209
2024
Q1 		$1.41M Sell
160,532
-5,440
-3% -$29.1K 0.01% 831
2023
Q4 		$710K Sell
165,972
-4,059
-2% -$14.3K 0.01% 1109
2023
Q3 		$580K Sell
170,031
-1,434
-0.8% -$6.51K 0.01% 1106
2023
Q2 		$967K Sell
171,465
-650
-0.4% -$3.36K 0.01% 886
2023
Q1 		$831K Sell
172,115
-723
-0.4% -$3.8K 0.01% 866
2022
Q4 		$1.04K Buy
172,838
+1,819
+1% +$9.11K ﹤0.01% 3025
2022
Q3 		$817K Buy
171,019
+1,047
+0.6% +$5.63K 0.01% 732
2022
Q2 		$971K Buy
169,972
+201
+0.1% +$1.2K 0.02% 677
2022
Q1 		$1.21M Buy
169,771
+2,665
+2% +$17.8K 0.02% 579
2021
Q4 		$1.33M Buy
167,106
+11,247
+7% +$103K 0.02% 605
2021
Q3 		$1.74M Buy
155,859
+4,543
+3% +$58.8K 0.04% 354
2021
Q2 		$2.21M Buy
+151,316
New +$2.34M 0.06% 282

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NewEdge Advisors's LTRN Position: Q1 2026 in Review

NewEdge Advisors reduced its Lantern Pharma (LTRN) stake by 28% in Q1 2026, selling an estimated $29.8K and leaving 27,399 shares worth $37.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3012.

NewEdge Advisors first reported a position in LTRN in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.21M in Q2 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • NewEdge Advisors held 27,399 shares of Lantern Pharma worth $37.5K as of Q1 2026.
  • NewEdge Advisors sold 10,670 Lantern Pharma shares in Q1 2026, an estimated $29.8K.
  • Lantern Pharma made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3012 holding.
  • NewEdge Advisors first reported a position in Lantern Pharma in Q2 2021 and has held it in 20 quarters since.
  • NewEdge Advisors's Lantern Pharma position peaked at $2.21M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.